The goal of this pilot trial is to to evaluate the preliminary effect of oral colchicine therapy on graft outcomes in patients underwent primary isolated CABG. The main questions it aims to answer is: 1. Whether the oral colchicine therapy may reduce the failure outcome of grafts after CABG. 2. Whether it is feasible to construct a muticenter powered trial to test the superiority hypothesis. Researchers will compare colchicine to none to see if colchicine works. Participants will 1. Take oral colchicine (0.5mg daily) therapy for 12 months after CABG. 2. Clinical follow-up at Month 1, 6, and 12 after CABG. 3. Protocol-driven CCTA at Week 1 and Month 12 after CABG.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
100
Oral Colchicine 0.5mg qd for 1 year
Ruijin Hospital Shanghai Jiao Tong University School of Medicine
Shanghai, China
RECRUITINGThe Graft Failure Rate at 1 year
A protocol-driven CCTA will be used to evaluate the graft outcome at 1 year after CABG. Fitzgibbon Grade B/S/O is definned as graft failure.
Time frame: at 1 year post-CABG
The time to first 5-point Major Adverse Cardiovascular Event (MACE-5)
MACE-5 is a composite of all-cause death, myocardial infarction, stroke, unplanned revascularization, and rehospitalization due to unstable angina.
Time frame: within 1 year post-CABG
The rate of new perioperative atrial fibrillationat (PAF) within 1 week after CABG
PAF will be detected through continuous electrocardiographic monitoring.
Time frame: within 7 days post-CABG
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.